Julius Lindblom

929 total citations
43 papers, 566 citations indexed

About

Julius Lindblom is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Julius Lindblom has authored 43 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Rheumatology, 26 papers in Immunology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Julius Lindblom's work include Systemic Lupus Erythematosus Research (37 papers), Atherosclerosis and Cardiovascular Diseases (13 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). Julius Lindblom is often cited by papers focused on Systemic Lupus Erythematosus Research (37 papers), Atherosclerosis and Cardiovascular Diseases (13 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). Julius Lindblom collaborates with scholars based in Sweden, Italy and United States. Julius Lindblom's co-authors include Ioannis Parodis, Chandra Mohan, Raija Korpelainen, Irene Vikman, Maarit Kangas, Timo Jämsä, Lars Nyberg, Alvaro Gómez, Alexander Borg and Pia Enebrink and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and BMJ.

In The Last Decade

Julius Lindblom

37 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julius Lindblom Sweden	13	287	181	91	86	71	43	566
Anke Salmen Switzerland	17	102 0.4×	104 0.6×	30 0.3×	51 0.6×	20 0.3×	91	898
Paul Browne United States	8	140 0.5×	126 0.7×	9 0.1×	39 0.5×	27 0.4×	13	1.1k
Sean Donohue United States	9	138 0.5×	121 0.7×	7 0.1×	30 0.3×	55 0.8×	16	645
Christopher McGuigan Ireland	18	93 0.3×	98 0.5×	7 0.1×	10 0.1×	25 0.4×	58	900
Hernán Inojosa Germany	11	55 0.2×	41 0.2×	15 0.2×	16 0.2×	56 0.8×	26	589
Owen Pearson United Kingdom	13	80 0.3×	76 0.4×	6 0.1×	15 0.2×	23 0.3×	29	708
T. Moreau France	10	100 0.3×	251 1.4×	7 0.1×	160 1.9×	20 0.3×	23	884
Jina Pakpoor United States	11	34 0.1×	35 0.2×	26 0.3×	27 0.3×	75 1.1×	31	500
Andrea Werdecker Germany	2	96 0.3×	86 0.5×	4 0.0×	24 0.3×	20 0.3×	2	759
Jun-Ki Min South Korea	6	135 0.5×	76 0.4×	35 0.4×	8 0.1×	10 0.1×	12	414

Countries citing papers authored by Julius Lindblom

Since Specialization

Citations

This map shows the geographic impact of Julius Lindblom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julius Lindblom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julius Lindblom more than expected).

Fields of papers citing papers by Julius Lindblom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julius Lindblom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julius Lindblom. The network helps show where Julius Lindblom may publish in the future.

Co-authorship network of co-authors of Julius Lindblom

This figure shows the co-authorship network connecting the top 25 collaborators of Julius Lindblom. A scholar is included among the top collaborators of Julius Lindblom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julius Lindblom. Julius Lindblom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grosso, Giorgia, et al.. (2025). Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials. Lara D. Veeken. 64(7). 4257–4266. 1 indexed citations

Parodis, Ioannis, Julius Lindblom, Helena Idborg, et al.. (2025). New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity–could anti-LIN28A enhance precision in diagnostics?. Annals of the Rheumatic Diseases. 84(7). 1180–1194. 2 indexed citations

Lindblom, Julius, Guillermo Barturen, Lorenzo Beretta, et al.. (2025). Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus. Journal of Translational Autoimmunity. 11. 100296–100296.

Lindblom, Julius, Luca Iaccarino, Andrea Doria, et al.. (2025). Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab. Lara D. Veeken. 64(8). 4650–4658. 1 indexed citations

Lindblom, Julius, et al.. (2025). Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1. Annals of the Rheumatic Diseases. 84(7). 1164–1179. 2 indexed citations

Garantziotis, Panagiotis, Julius Lindblom, Dionysis Nikolopoulos, et al.. (2025). DISTINCT MOLECULAR PROFILES OF REMISSION POST-CD19 CAR-T CELL THERAPY VERSUS STANDARD IMMUNOSUPPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS. The Journal of Rheumatology. 52(Suppl 1). 8–8.

Nikolopoulos, Dionysis, et al.. (2024). Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity. Lara D. Veeken. 63(9). 2494–2502. 8 indexed citations

Nikolopoulos, Dionysis, et al.. (2024). Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials. Rheumatology International. 44(9). 1679–1689. 3 indexed citations

Parodis, Ioannis, Julius Lindblom, Guillermo Barturen, et al.. (2024). Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. Annals of the Rheumatic Diseases. 83(7). 889–900. 14 indexed citations

10.

Tan, Ying, Julius Lindblom, Junjun Zheng, et al.. (2023). Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics. Clinical Immunology. 254. 109713–109713. 9 indexed citations

11.

Lindblom, Julius, et al.. (2023). Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab. Lara D. Veeken. 63(3). 798–808. 10 indexed citations

12.

Gómez, Alvaro, Julius Lindblom, Sharzad Emamikia, et al.. (2023). Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State. Lara D. Veeken. 62(12). 3916–3923. 3 indexed citations

13.

Palazzo, L., et al.. (2023). POS1467 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB. Annals of the Rheumatic Diseases. 82. 1088–1088. 1 indexed citations

14.

Lindblom, Julius, Lorenzo Beretta, María Orietta Borghi, Marta E. Alarcón‐Riquelme, & Ioannis Parodis. (2023). Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Frontiers in Immunology. 14. 1257085–1257085. 12 indexed citations

15.

Borg, Alexander, Julius Lindblom, Alvaro Gómez, et al.. (2023). Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus. Frontiers in Medicine. 10. 1247354–1247354. 5 indexed citations

16.

Parodis, Ioannis, et al.. (2022). Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. Frontiers in Medicine. 9. 852162–852162. 9 indexed citations

17.

Lindblom, Julius, Sharzad Emamikia, Alexander Borg, et al.. (2022). EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus. Frontiers in Medicine. 9. 1092325–1092325. 9 indexed citations

18.

Lindblom, Julius, et al.. (2022). POS0187 DRUG REPURPOSING FOR TREATING LUPUS NEPHRITIS BASED ON TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS. Annals of the Rheumatic Diseases. 81. 326–326. 1 indexed citations

19.

Gómez, Alvaro, Alexander Borg, Julius Lindblom, et al.. (2021). Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus. Frontiers in Medicine. 8. 651249–651249. 42 indexed citations

20.

Långström, Niklas, et al.. (2013). Preventing sexual abusers of children from reoffending: systematic review of medical and psychological interventions. BMJ. 347(aug09 1). f4630–f4630. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact